These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21160478)

  • 1. Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
    Suzuki J; Otsuka F; Inagaki K; Tanabe K; Tsukamoto N; Miyoshi T; Nakamura E; Ogura T; Kumagai I; Makino H
    Hypertens Res; 2011 Mar; 34(3):404-6. PubMed ID: 21160478
    [No Abstract]   [Full Text] [Related]  

  • 2. Eplerenone, amlodipine and experimental hypertension: one plus one equals three.
    Funder JW
    Hypertens Res; 2011 Jul; 34(7):795-6. PubMed ID: 21614006
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats.
    Hao L; Kanno Y; Fukushima R; Watanabe Y; Ishida Y; Suzuki H
    Am J Nephrol; 2004; 24(1):54-60. PubMed ID: 14707436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F; Khankin E; Yaccob A; Kawachi H; Karram T; Awaad H; Nakhoul N; Hoffman A; Abassi Z
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty.
    Ibuki C; Kawamata H; Seino Y; Mizuno K
    Intern Med; 2010; 49(22):2455-9. PubMed ID: 21088349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone (GD Searle & Co).
    Martin J; Krum H
    Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of captopril on both hypertension and proteinuria. Report of a case of renovascular hypertension associated with nephrotic syndrome.
    Takeda R; Morimoto S; Uchida K; Kigoshi T; Sumitani T; Matsubara F
    Arch Intern Med; 1980 Nov; 140(11):1531-3. PubMed ID: 7002084
    [No Abstract]   [Full Text] [Related]  

  • 13. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Eplerenone in resistant hypertension with previous spironolactone intolerance].
    Antonio Costa J; Rodilla E; Pérez-Lahiguera F; María Pascual J
    Med Clin (Barc); 2009 May; 132(19):756-7. PubMed ID: 19243793
    [No Abstract]   [Full Text] [Related]  

  • 15. New antihypertensive drug class.
    Am J Nurs; 2003 Apr; 103(4):111. PubMed ID: 12677125
    [No Abstract]   [Full Text] [Related]  

  • 16. Eplerenone.
    Brown R; Quirk J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 Mar; 2(3):177-8. PubMed ID: 12619638
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
    Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Kihara Y
    Int J Cardiol; 2014; 172(1):e180-1. PubMed ID: 24439863
    [No Abstract]   [Full Text] [Related]  

  • 18. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of renovascular hypertension with the nephrotic syndrome.
    Fujioka S; Sasakawa O; Suzuki R; Nogi O; Tsumura K; Komori T; Morii H
    Jpn J Med; 1986 Aug; 25(3):317-20. PubMed ID: 3534395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.